Luciana Ansaneli Naves

Luciana Ansaneli Naves

Auto-generated profile, based on publicly available information

Luciana Ansaneli Naves

University of Brasilia

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2009 in Pituitary
Verified
Journal Article
Closed access
PDF file
LVLucio Vilar
Lucio Vilar
LNLuciana A. Naves
Luciana A. Naves
MAMonalisa F. Azevedo
Monalisa F. Azevedo
MAMaria Juliana Arruda
Maria Juliana Arruda
CACarla M. Arahata
Carla M. Arahata
VCViviane Canadas
Viviane Canadas

25 November 2015 in Endocrine
Verified
Journal Article
Closed access
PDF file
LNLuciana A. Naves
Luciana A. Naves
ADAdrian Daly
Adrian Daly
LDLuiz Augusto Dias
Luiz Augusto Dias
BYBo Yuan
Bo Yuan
JZJuliano Coelho Oliveira Zakir
Juliano Coelho Oliveira Zakir
ABAlbert Beckers
Albert Beckers

1 December 2004 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
LCLuiz Augusto Casulari
Luiz Augusto Casulari
LNLuciana A. Naves
Luciana A. Naves
PMPaulo A. Mello
Paulo A. Mello
ANAldo Pereira Neto
Aldo Pereira Neto
CPCarla Papadia
Carla Papadia
A woman affected by Cushing’s disease underwent bilateral adrenalectomy followed by radiotherapy of the hypothalamic-pituitary area when she was 18 years old. Thereafter, she used hydrocortisone acetate replacement therapy (35.5 mg divided into two daily doses). At the age of 26 years, the patient exhibited the clinical signs of the Nelson’s syndrome, i.e. skin and gingival hyperpigmentation accompanied by amenorrhea, and elevated ACTH plasma levels (2,850 pg/ml, normal range 15–80 pg/ml). The magnetic resonance imaging (MRI) analysis of the sellar region evidenced a pituitary macroadenoma, measuring 14 × 13 mm. The patient was initially treated with cyproheptadine hydrochloride (12 mg/day) for 18 months. There was a partial improvement of the symptoms, with a reduction of the ACTH plasma levels to 112 pg/ml, but without any modification of the tumor mass. Due to sleepiness and weight gain, the cyproheptadine treatment was interrupted and substituted by a cabergoline (0.5 mg twice a week) therapy. Soon after cabergoline was applied an improvement of the clinical symptoms and signs was observed such as a regression of the tumor mass and the normalization of the ACTH plasma titers (38 pg/ml). Later, cabergoline was substituted by bromocriptine (7.5 mg/day) and the plasma levels of ACTH increased again (247 pg/ml), and headache and cutaneous hyperpigmentation were recorded. When cabergoline was reintroduced there was a clinical improvement and normalization of ACTH plasma levels (64 pg/ml). The MRI analysis of the sella region demonstrated a complete remission of the pituitary adenoma. The results obtained show for the first time that a long-term treatment with cabergoline also brings about a complete remission of Nelson’s syndrome in the presence of a pituitary macroadenoma.

1 January 2007 in Gynecological Endocrinology
Verified
Journal Article
Closed access
RFRoberpaulo Barboza Filho
Roberpaulo Barboza Filho
LDLucilia Domingues
Lucilia Domingues
LNLuciana Naves
Luciana Naves
EFElenice Ferraz
Elenice Ferraz
AAAdriana Alves
Adriana Alves
LCLuiz Augusto Casulari
Luiz Augusto Casulari
The aims of the present study were to identify the cause of hyperprolactinemia in polycystic ovary syndrome (PCOS) and to compare prolactin (PRL) levels between PCOS women without hyperprolactinemia and women with insulin resistance and without PCOS. A group of 82 women (age: 27.1 ± 7.6 years) with PCOS was included in the study. Their PRL levels were measured and compared with those of women with insulin resistance without PCOS (controls; n = 42; age: 29.2 ± 8.2 years). Among the 82 PCOS women, 13 (16%) presented high PRL levels (103.9 ± 136.0 μg/l). The causes of hyperprolactinemia were: pituitary tumor (responding to cabergoline) in nine cases (69%; PRL range: 28.6 – 538 μg/l); oral hormonal contraceptive treatment in two cases (15%; PRL: 46 and 55 μg/l, respectively); and use of buspirone and tianeptine in one case (8%; PRL: 37.1 μg/l); one case (8%; PRL: 34.4 μg/l) had macroprolactinemia. In drug-induced hyperprolactinemic patients PRL levels normalized after treatment interruption. The average PRL level in the 69 remaining patients was 12.1 ± 5.5 μg/l, a value not statistically different from that of the control group (11.8 ± 4.9 μg/l). This result leads us to conclude that PCOS patients with increased PRL levels must be investigated for other causes of hyperprolactinemia, because hyperprolactinemia is not a clinical manifestation of PCOS.

1 November 2007 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LVLucio Vilar
Lucio Vilar
MFMaria da Conceição Freitas
Maria da Conceição Freitas
MFManuel Faria
Manuel Faria
RMRenan Montenegro
Renan Montenegro
LCLuiz Augusto Casulari
Luiz Augusto Casulari
OBOscar D. Bruno
Oscar D. Bruno
Among endocrine disorders, Cushing's syndrome (CS) is certainly one of the most challenging to endocrinologists due to the difficulties that often appear during investigation. The diagnosis of CS involves two steps: confirmation of hypercortisolism and determination of its etiology. Biochemical confirmation of the hypercortisolaemic state must be established before any attempt at differential diagnosis. Failure to do so will result in misdiagnosis, inappropriate treatment, and poor management. It should also be kept in mind that hypercortisolism may occur in some patients with depression, alcoholism, anorexia nervosa, generalized resistance to glucocorticoids, and in late pregnancy. Moreover, exogenous or iatrogenic hypercortisolism should always be excluded. The three most useful tests to confirm hypercortisolism are the measurement of 24-h urinary free cortisol levels, low-dose dexamethasone-suppression tests, and determination of midnight serum cortisol or late-night salivary cortisol. However, none of these tests is perfect, each one has different sensitivities and specificities, and several are usually needed to provide a better diagnostic accuracy. The greatest challenge in the investigation of CS involves the differentiation between Cushing's disease and ectopic ACTH syndrome. This task requires the measurement of plasma ACTH levels, non-invasive dynamic tests (high-dose dexamethasone suppression test and stimulation tests with CRH or desmopressin), and imaging studies. None of these tests had 100% specificity and their use in combination is usually necessary. Bilateral inferior petrosal sinus sampling is mainly indicated when non-invasive tests do not allow a diagnostic definition. In the present paper, the most important pitfalls in the investigation of CS are reviewed.

21 November 2010 in Pituitary
Verified
Journal Article
Closed access
PDF file
LVLucio Vilar
Lucio Vilar
MAMonalisa F. Azevedo
Monalisa F. Azevedo
LNLuciana Ansaneli Naves
Luciana Ansaneli Naves
LCLuiz Augusto Casulari
Luiz Augusto Casulari
JAJosé Luciano Albuquerque
José Luciano Albuquerque
MFManuel S. Faria
Manuel S. Faria